Symbol="CCCC"
AssetType="Common Stock"
Name="C4 TherapeuticsÂ Inc"
Description="C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts."
CIK="1662579"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="490 ARSENAL WAY, SUITE 200, WATERTOWN, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="142654000"
EBITDA="-142638000"
PERatio="None"
PEGRatio="None"
BookValue="4.763"
DividendPerShare="0"
DividendYield="0"
EPS="-2.65"
RevenuePerShareTTM="0.327"
ProfitMargin="0"
OperatingMarginTTM="-9.02"
ReturnOnAssetsTTM="-0.208"
ReturnOnEquityTTM="-0.484"
RevenueTTM="16031000"
GrossProfitTTM="-86745000"
DilutedEPSTTM="-2.65"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.807"
AnalystTargetPrice="17.64"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="8.15"
PriceToBookRatio="1.208"
EVToRevenue="3.285"
EVToEBITDA="-1.541"
Beta="2.022"
num_52WeekHigh="12.61"
num_52WeekLow="2.6"
num_50DayMovingAverage="3.353"
num_200DayMovingAverage="4.887"
SharesOutstanding="49190900"
DividendDate="None"
ExDividendDate="None"
symbol="CCCC"
open="2.95"
high="2.97"
low="2.90"
price="2.90"
volume="199165.00"
latest_trading_day="2023-08-31"
previous_close="2.93"
change="-0.03"
change_percent="-1.0239%"
aroon_positive_momentum_days="43"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="43"
Volume_recent_avg="927074"
Change_recent_avg="-0.01"
Delta_recent_avg="0.22"
Variance_recent_avg="0.11"
Change_ratio_recent_avg="-0.44"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="43"
Aroon_momentum_negative="57"
image_negative_thumbnail_id_1="110"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0066.jpeg"
image_negative_thumbnail_id_2="152"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0024.jpeg"
image_neutral_thumbnail_id_1="547"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0052.jpeg"
image_neutral_thumbnail_id_2="580"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0019.jpeg"
image_positive_thumbnail_id_1="650"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0058.jpeg"
image_positive_thumbnail_id_2="688"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0020.jpeg"
image_professor_thumbnail_id_1="1173"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
image_professor_thumbnail_id_2="1177"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0011.jpeg"
